FrancophonIA/ELRC3.0 huggingface dataset:
English: 5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
Estonian: 3 Kontrollitud kliinilistes uuringutes täheldati turseid 6…9%-l patsientidest, keda raviti pioglitasooniga ühe aasta jooksul.
English: Pioglitazone Teva Pharma 15 mg tablets Pioglitazone Teva Pharma 30 mg tablets Pioglitazone Teva Pharma 45 mg tablets
Estonian: Pioglitazone Teva Pharma 15 mg tabletid Pioglitazone Teva Pharma 30 mg tabletid Pioglitazone Teva Pharma 45 mg tabletid
English: Pioglitazone Teva Pharma 15 mg tablets Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets
Estonian: Pioglitazone Teva Pharma 15 mg tabletid Alumiinium/alumiinium blisterid 14, 28, 30, 50, 56, 84, 90, 98, 112 ja 196 tabletiga pakendid.
English: - Pioglitazone Teva Pharma 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side.
Estonian: - Pioglitazone Teva Pharma 30 mg tabletid on valged kuni kahvatuvalged ümmargused kumerad tabletid, mille ühele küljele on pressitud number „30“ ja teisele küljele „Teva“.
English: Pioglitazone Teva Pharma 45 mg tablets EU/1/12/758/021-030
Estonian: Pioglitazone Teva Pharma 45 mg tabletid EU/1/12/758/021-030
English: Pioglitazone Teva Pharma 15 mg tablets EU/1/12/758/001-010
Estonian: Pioglitazone Teva Pharma 15 mg tabletid EU/1/12/758/001-010
English: - Pioglitazone Teva Pharma 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side.
Estonian: - Pioglitazone Teva Pharma 45 mg tabletid on valged kuni kahvatuvalged ümmargused kumerad tabletid, mille ühele küljele on pressitud number „45“ ja teisele küljele „Teva“.
English: How to take Pioglitazone Teva Pharma
Estonian: Kuidas Pioglitazone Teva Pharma't võtta
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 March 2012
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV
English: Pioglitazone Teva Pharma 30 mg tablets EU/1/12/758/011-020
Estonian: Pioglitazone Teva Pharma 30 mg tabletid EU/1/12/758/011-020
English: - The tablets are supplied in Aluminium/aluminium blisters in packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets or 50 x 1 tablets in Aluminium/aluminium perforated unit dose blisters.
Estonian: - Tabletid on saadaval alumiinium/alumiinium blistrites, tarnituna pakendites, mis sisaldavad 14, 28, 30, 50, 56, 84, 90, 98, 112 või 196 tabletti, või 50 × 1 tabletti alumiinium/alumiinium perforeeritud üksikannuse blistrites.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/021-030
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/12/758/021-030
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/011-020
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/12/758/011-020
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/758/001-010
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/12/758/001-010
English: The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily.
Estonian: Tavaline algannus on üks 15 mg või 30 mg tablett pioglitasooni üks kordööpäevas.
English: Take Pioglitazone Teva Pharma daily as prescribed.
Estonian: Kui te unustate Pioglitazone Teva Pharma't võtta Püüdke Pioglitazone Teva Pharma't võtta ettekirjutuse järgi iga päev.
English: Pioglitazone Teva Pharma 30 mg tablets
Estonian: Pioglitazone Teva Pharma 30 mg tabletid
English: Warnings and precautions Talk to your doctor or pharmacist before taking Pioglitazone Teva Pharma (also see section 4)
Estonian: Enne Pioglitazone Teva Pharma kasutamist pidage nõu oma arsti või apteekriga (vt ka lõik 4): - kui teil esineb vedelikupeetus (vedeliku retentsioon) või südamepuudulikkus, eriti kui olete üle
English: - If you get any side effects, talk to your doctor or pharmacist.
Estonian: - Kui teil tekib ükskõik milline kõrvaltoimete, pidage nõu oma arsti või apteekriga.
English: How to store Pioglitazone Teva Pharma
Estonian: Kuidas Pioglitazone Teva Pharma't säilitada
English: Pioglitazone Teva Pharma 45 mg tablets
Estonian: Pioglitazone Teva Pharma 45 mg tabletid
English: prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).
Estonian: Pikaajalise ravi potentsiaalseid riske arvestades peavad ravi määranud arstid järgnevate tavapäraste visiitide käigus saama kinnitust, et pioglitasoonist saadud kasu püsib (vt lõik 4.4).
English: Pioglitazone Teva Pharma 15 mg tablets
Estonian: Pioglitazone Teva Pharma 15 mg tabletid
English: Each Pioglitazone Teva Pharma 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride).
Estonian: Iga Pioglitazone Teva Pharma 30 mg tablett sisaldab 30 mg pioglitasooni (vesinikkloriidina).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 45 mg pioglitazone (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 45 mg pioglitasooni (vesinikkloriidina).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 30 mg pioglitazone (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 30 mg pioglitasooni (vesinikkloriidina).
English: Each Pioglitazone Teva Pharma 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride).
Estonian: Iga Pioglitazone Teva Pharma 45 mg tablett sisaldab 45 mg pioglitasooni (vesinikkloriidina).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 15 mg pioglitazone (as hydrochloride).
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 15 mg pioglitasooni (vesinikkloriidina).
English: Pioglitazone Teva Pharma 30 mg tablets Each tablet contains 30 mg of pioglitazone (as hydrochloride).
Estonian: Pioglitazone Teva Pharma 30 mg tabletid Iga tablett sisaldab 30 mg pioglitasooni (vesinikkloriidina).
English: common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon alanine aminotransferase increased7
Estonian: vere kreatiini fosfokinaasi tõus laktaadi dehüdro aeg-ajalt
English: INFORMATION IN BRAILLE Pioglitazone Teva Pharma 30 mg tablets
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) pioglitazone teva pharma 30 mg
English: INFORMATION IN BRAILLE Pioglitazone Teva Pharma 45 mg tablets
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) pioglitazone teva pharma 45 mg
English: Pioglitazone Teva Pharma 45 mg tablets Each tablet contains 45 mg of pioglitazone (as hydrochloride).
Estonian: Pioglitazone Teva Pharma 45 mg tabletid Iga tablett sisaldab 45 mg pioglitasooni (vesinikkloriidina).
English: Each Pioglitazone Teva Pharma 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride).
Estonian: Iga Pioglitazone Teva Pharma 15 mg tablett sisaldab 15 mg pioglitasooni (vesinikkloriidina).
English: Pioglitazone Teva Pharma 15 mg tablets Each tablet contains 15 mg of pioglitazone (as hydrochloride).
Estonian: Pioglitazone Teva Pharma 15 mg tabletid Iga tablett sisaldab 15 mg pioglitasooni (vesinikkloriidina).
English: NAME OF THE MEDICINAL PRODUCT Pioglitazone Teva Pharma 30 mg tablets Pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Pioglitazone Teva Pharma 30 mg tabletid Pioglitasoon
English: NAME OF THE MEDICINAL PRODUCT Pioglitazone Teva Pharma 45 mg tablets Pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Pioglitazone Teva Pharma 45 mg tabletid Pioglitasoon
English: Posology
Estonian: Silma
English: Do not take Pioglitazone Teva Pharma - if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
Estonian: Ärge võtke Pioglitazone Teva Pharma't - kui olete toimeaine või selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6) suhtes allergiline; - kui teil esineb või on olnud südamepuudulikkus; - kui teil esineb maksahaigus; - kui teil on olnud diabeetiline ketoatsidoos (diabeedi tüsistus, mis põhjustab kiiret kaalukaotust,
English: INFORMATION IN BRAILLE Pioglitazone Teva Pharma 15 mg tablets
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) pioglitazone teva pharma 15 mg
English: - The tablets are supplied in Aluminium/aluminium blisters in packs of 14, 28, 30, 50, 56, 84, 90,
Estonian: - Tabletid on saadaval alumiinium/alumiinium blistrites, tarnituna pakendites, mis sisaldavad 14, 28, 30, 50, 56, 84, 90, 98, 112 või 196 tabletti.
English: NAME OF THE MEDICINAL PRODUCT Pioglitazone Teva Pharma 15 mg tablets Pioglitazone
Estonian: RAVIMPREPARAADI NIMETUS Pioglitazone Teva Pharma 15 mg tabletid Pioglitasoon
English: Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin dizziness common insomnia uncommon uncommon uncommon uncommon uncommon
Estonian: Monoravi kombineeritud koos metformiiniga koos sulfonüüluureaga koos metformiini ja sulfonüüluureaga koos insuliiniga kahjustused nägemishäired2
English: What measures are being taken to ensure the safe and effective use of Palynziq?
Estonian: Mis meetmed võetakse, et tagada Palynziqi ohutu ja efektiivne kasutamine?
English: Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu309708.
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav: ema.europa.eu/medicines/human/orphan-designations/eu309708.
English: The European Medicines Agency therefore decided that Palynziq's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Palynziqi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The recommended starting dose is 2.5 mg once a week for 4 weeks.
Estonian: Soovitatav algannus on 2,5 mg üks kord nädalas 4 nädala jooksul.
English: Palynziq (pegvaliase)
Estonian: Palynziq (pegvaliaas)
English: Palynziq is intended for long-term use.
Estonian: Palynziq on ette nähtud pikaajaliseks kasutamiseks.
English: The dose and frequency of injection are then increased gradually (up to a maximum dose of 60 mg once a day) to achieve adequate control of phenylalanine blood levels.
Estonian: Annust ja süstimissagedust võib seejärel järk-järgult suurendada (kuni maksimumannuseni 60 mg üks kord ööpäevas), et saavutada vere fenüülalaniinisisalduse piisav ohjamine.
English: Further information on Palynziq can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Palynziq.
Estonian: Lisateave Palynziqi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Palynziq.
English: The most significant allergic reactions include acute systemic allergic reaction, angioedema (swelling under the skin in areas such as the face, throat, arms and legs), and serum sickness (allergic reaction caused by animal proteins or serum).
Estonian: Kõige olulisemad allergilised reaktsioonid on äge süsteemne allergiline reaktsioon, angioödeem (nahaalune turse teatud piirkondades, näiteks nägu, kõri, üla- ja alajäsemed) ning seerumtõbi (loomvalkude või -seerumi põhjustatud allergiline reaktsioon).
English: Palynziq must be used with stringent measures to manage any serious allergic reactions, especially in the first few months.
Estonian: Palynziqi kasutamisel tuleb võtta rangeid meetmeid, et iga raske allergiline reaktsioon, eriti esimestel kuudel, oleks hallatav.
English: What is Palynziq and what is it used for?
Estonian: Mis on Palynziq ja milleks seda kasutatakse?
English: The safety of Palynziq is considered acceptable, and important side effects such as allergic reactions are considered manageable with additional stringent measures (see below).
Estonian: Palynziqi ohutust peeti vastuvõetavaks ning olulisi kõrvalnähte (nt allergilisi reaktsioone) hallatavateks täiendavate rangete meetmete võtmisel (vt allpool).
English: As for all medicines, data on the use of Palynziq are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Palynziqi kasutamise kohta pidevat järelevalvet.
English: For more information about using Palynziq, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Palynziqi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Palynziq contains the active substance pegvaliase.
Estonian: Palynziq sisaldab toimeainena pegvaliaasi.
English: Palynziq is available as pre-filled syringes (2.5, 10 and 20 mg) for injection under the skin.
Estonian: Palynziqit turustatakse eeltäidetud süstaldes (2,5 mg, 10 mg ja 20 mg) subkutaanseks (naha alla) süstimiseks.
English: The company that markets Palynziq will provide information material for doctors and for patients and carers about the risk of allergic reactions with Palynziq, including how to identify them promptly and what to do in case such a reaction occurs.
Estonian: Palynziqi turustaja annab arstidele, patsientidele ja nende hooldajatele teabematerjali Palynziqiga seotud allergiliste reaktsioonide riski kohta, sh kuidas neid kohe ära tunda ja mida teha, kui selline reaktsioon tekib.
English: Palynziq must not be used in patients who have had an allergic reaction to pegvaliase, to any of the other components of Palynziq or to any other pegylated medicine.
Estonian: Palynziqit ei tohi kasutada patsiendid, kellel on esinenud allergiline reaktsioon pegvaliaasi, Palynziqi mis tahes muu koostisosa või mis tahes muu pegüleeritud ravimi suhtes.
English: During treatment, monthly measurements are recommended.
Estonian: Ravi ajal soovitatakse seda määrata üks kord kuus.
English: In the extension phase of the study patients received an individual optimized dose of Palynziq.
Estonian: Uuringu jätkufaasis said patsiendid individuaalselt optimeeritud Palynziqi annust.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Palynziq have also been included in the summary of product characteristics and the package leaflet.
Estonian: Palynziqi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The enzyme in pegvaliase is ‘pegylated' (attached to a chemical called PEG), allowing it to remain in the body and to act for longer.
Estonian: Pegvaliaasis sisalduv ensüüm on pegüleeritud (seotud polüetüleenglükooliga (PEG)), mis võimaldab ensüümil organismis püsida ja toimida kauem.
English: Side effects reported with Palynziq are carefully evaluated and any necessary action taken to protect patients.
Estonian: Palynziqi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Other information about Palynziq
Estonian: Muu teave ravimi Palynziq kohta
English: Throughout the study, patients were required to maintain a constant level of dietary protein intake, to ensure that changes in blood phenylalanine levels could be attributed to treatment rather than to changes in protein intake.
Estonian: Kogu uuringu jooksul pidid patsiendid säilitama valkude muutumatu koguse toidus, tagamaks, et vere fenüülalaniinisisalduse muutusi saaks seostada pigem raviga kui sissevõetava valgu muutustega.
English: The most common side effects with Palynziq (which may affect more than 7 in 10 people) are reactions at the injection site, pain in the joints and allergic reactions.
Estonian: Palynziqi kõige sagedamad kõrvalnähud (võivad esineda enam kui 7 patsiendil 10st) on süstekoha reaktsioonid, liigesevalu ja allergilised reaktsioonid.
English: Patients with this genetic disease cannot process the amino acid phenylalanine from dietary protein, and as a result the amino acid builds up in the blood to abnormally high levels, causing problems in the nervous system.
Estonian: Selle geneetilise haigusega patsientide organism ei töötle toiduvalguga saadavat aminohapet fenüülalaniini, mistõttu tekib veres selle aminohappe ebanormaalselt suur sisaldus, mis põhjustab närvisüsteemi probleeme.
English: Palynziq is a medicine that is used to treat phenylketonuria (PKU) in adults and adolescents from 16 years of age.
Estonian: Palynziq on ravim, mida kasutatakse fenüülketonuuriaga (PKU) täiskasvanute ja vähemalt 16-aastaste noorukite raviks.
English: Palynziq was shown to be effective at reducing levels of blood phenylalanine and keeping them under control.
Estonian: Palynziq oli efektiivne vere fenüülalaniinisisalduse vähendamisel ja selle kontrolli all hoidmisel.
English: Palynziq is used in patients whose blood levels of phenylalanine have not been adequately controlled with other treatments.
Estonian: Palynziqit kasutatakse patsientidel, kellel vere fenüülalaniinisisaldus ei ole piisavalt hallatav muu raviga.
English: The main study investigating Palynziq in patients with PKU consisted of different parts.
Estonian: Põhiuuring, milles vaadeldi Palynziqi toimet fenüülketonuuriaga patsientidele, koosnes eri osadest.
English: After 8 weeks of treatment, blood phenylalanine levels remained under control in patients taking Palynziq but they returned to pre-treatment levels in patients on placebo, showing that Palynziq was more effective than placebo in reducing blood phenylalanine levels and keeping them within an acceptable range.
Estonian: Pärast 8 ravinädalat jäi patsientidel, kes said Palynziqit, vere fenüülalaniinisisaldus hallatavaks, kuid platseebot saanud patsientidel suurenes see ravieelse tasemeni, mis tõendab, et Palynziq oli efektiivsem kui platseebo vere fenüülalaniinisisalduse vähendamisel ning selle hoidmisel vastuvõetavas vahemikus.
English: How does Palynziq work?
Estonian: Kuidas Palynziq toimib?
English: Palynziq was designated an ‘orphan medicine' (a medicine used in rare diseases) on 28 January 2010.
Estonian: Haigus esineb harva ja Palynziq nimetati 28. jaanuaril 2010 harvikravimiks.
English: What are the risks associated with Palynziq?
Estonian: Mis riskid Palynziqiga kaasnevad?
English: For the full list of side effects of Palynziq, see the package leaflet.
Estonian: Palynziqi kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It was shown that for the majority of patients continued treatment with Palynziq for 18 months was effective at keeping blood phenylalanine levels under control (below 600 micromoles per litre).
Estonian: Tõendati, et enamikul patsientidest oli 18-kuuline jätkuravi Palynziqiga efektiivne vere fenüülalaniinisisalduse vähendamisel ning selle kontrolli all hoidmisel (alla 600 mikromooli liitris).
English: The active substance in Palynziq, pegvaliase, is a bacterial enzyme that can break down phenylalanine, thereby stopping phenylalanine from building up in the body and helping to relieve the symptoms of phenylketonuria.
Estonian: Palynziq sisaldab toimeainena bakteriaalset ensüümi pegvaliaasi, mis lagundab fenüülalaniini, peatades seega fenüülalaniini kuhjumise organismis ja aidates leevendada fenüülketonuuria sümptomeid.
English: The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating PKU.
Estonian: Ravi tohib alustada fenüülketonuuria ravis kogenud arst ja see peab toimuma tema järelevalve all.
English: Phenylalanine blood levels must be measured before starting treatment.
Estonian: Enne ravi alustamist tuleb määrata vere fenüülalaniinisisaldus.
English: An overview of Palynziq and why it is authorised in the EU
Estonian: Ülevaade ravimist Palynziq ja ELis müügiloa väljastamise põhjendus
English: What benefits of Palynziq have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Palynziqi kasulikkus?
English: How is Palynziq used?
Estonian: Kuidas ravimit Palynziq kasutatakse?
English: Eighty-six patients who responded to treatment (i.e. whose blood phenylalanine levels were reduced by at least 20%) where then either kept on the same dose of Palynziq or were given placebo (a dummy treatment).
Estonian: Esimeses osas anti kõigile patsientidele kuni 13 nädala jooksul Palynziqit annuses 20 mg või 40 mg. 86 patsiendil, kellel tekkis ravivastus (vere fenüülalaniinisisaldus vähenes vähemalt 20% võrra), kas säilitati sama Palynziqi annus või anti neile edaspidi platseebot (näiv ravim).
English: Anise oil EMA/412178/2016
Estonian: Aniisiõli EMA/412178/2016
English: Pimpinella anisum L., aetheroleum
Estonian: Pimpinella anisum L., eeterlik õli
English: Aniseed oil medicines must not be used in children and adolescents under 18 years.
Estonian: Aniisiõli sisaldavaid ravimeid ei tohi kasutada lastel ja alla 18aastastel noorukitel.
English: Anise oil medicines should only be used in adults and should not be taken for longer than two weeks.
Estonian: Aniisiõli sisaldavaid ravimeid tohivad kasutada üksnes täiskasvanud ja neid ei tohi võtta kauem kui 2 nädalat.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 September 2016 EMA/412178/2016
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20.
English: They must also not be used in patients who are allergic to aniseed or to plants of the Apiaceae family (Umbelliferae) (caraway, celery, coriander, dill, fennel) or anethole.
Estonian: Neid ravimeid ei tohi kasutada ka patsiendid, kes on allergilised aniisi või sarikaliste sugukonda kuuluvate taimede (köömen, seller, koriander, till, apteegitill) või anetooli suhtes.
English: Anise oil
Estonian: Aniisiõli
English: What is anise oil?
Estonian: Mis on aniisiõli?
English: If symptoms last or get worse during the use of the medicine, a doctor or a qualified healthcare practitioner should be consulted.
Estonian: Kui sümptomid püsivad või ravimi kasutamise ajal süvenevad, peab konsulteerima arsti või
English: Other information about anise oil medicines
Estonian: Muu teave aniisiõli sisaldavate ravimite kohta
English: Further information on the risks associated with these anise oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave nende aniisiõli sisaldavate ravimitega kaasnevate riskide, sh nende ohutu kasutamise ettevaatusabinõude kohta, on taimse aine monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the HMPC assessment of anise oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave aniisiõli sisaldavate ravimite hindamise kohta, sh komitee kokkuvõtte üksikasjalik kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Detailed instructions on how to take anise oil medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Üksikasjalik teave, kuidas võtta aniisiõli sisaldavaid ravimeid ja kes neid tohib kasutada, on ravimi pakendi infolehel.
English: Any applications for the licensing of medicines containing anise oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Aniisiõli sisaldavate ravimite müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimsete ravimite müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslikke järeldusi.
English: What evidence supports the use of anise oil medicines?
Estonian: Mis tõendid toetavad aniisiõli sisaldavate ravimite kasutamist?
English: Information on the use and licensing of anise oil medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab aniisiõli sisaldavate ravimite kasutamise ja müügilubade teavet asjakohastelt riiklikelt ravimiametitelt.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of anise oil.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb aniisiõli meditsiinilisi kasutusviise.